Edwards Lifesciences (EW): Evaluating Valuation After Analyst Upgrades and Investor Day Growth Prospects

Piper Sandler has reaffirmed its positive outlook on Edwards Lifesciences (EW) ahead of the company’s annual investor day, highlighting ongoing momentum in the U.S. TAVR franchise and progress within the TMTT program. Recent financial results from Edwards have surpassed expectations, fueling greater analyst confidence in its future performance.

See our latest analysis for Edwards Lifesciences.

Edwards Lifesciences' upbeat momentum has been mirrored in its 17.3% year-to-date share price return. Bullish sentiment has strengthened after earnings topped estimates and talk of growth initiatives picked up speed. Looking longer term, the 1-year total shareholder return sits at an impressive 20.8%, suggesting that confidence in the company's prospects is building.

Curious about other medtech and healthcare stocks making moves this year? See the full list for free: See the full list for free.

With shares not far below analyst price targets and recent gains reflecting strong results, the question for investors is whether Edwards Lifesciences still offers a buying opportunity or if the market has already priced in its future growth.

Most Popular Narrative: 9.4% Undervalued

Edwards Lifesciences’ most widely followed narrative estimates a fair value of $93.94 per share, which is moderately above the latest closing price of $85.13. This suggests a gap between current market pricing and consensus expectations, indicating potential upside if the narrative’s core assumptions prove accurate.

“Recent clinical data, especially seven-year outcomes from major trials, are seen as reinforcing the durability and adoption potential of TAVR in low-risk patient groups. This could expand the addressable market. Positive surprises in new product data, particularly in the Evoque platform, are viewed as near-term catalysts for the company’s competitive positioning and market expansion.”

Read the complete narrative.

Want to know what drives this bullish outlook? The narrative’s calculation relies on strong future earnings and a premium profit multiple that is usually reserved for exceptional innovators. The specifics may surprise you. Discover what financial factors contribute to this eye-catching valuation.

Result: Fair Value of $93.94 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, downside risks remain. If TAVR growth slows or if there are unfavorable coverage decisions, the optimistic valuation narrative could be quickly undermined.

Find out about the key risks to this Edwards Lifesciences narrative.

Another View: Market Multiples Tell a Different Story

Looking at valuation a different way, Edwards Lifesciences trades at a price-to-earnings ratio of 36.8, which is notably higher than both its peer average of 32.6 and the broader US Medical Equipment sector average of 27.4. The SWS fair ratio is just 29, highlighting a gap that could mean the shares are overvalued if market sentiment shifts. Could this premium hold, or does it expose investors to valuation risk?

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own Edwards Lifesciences Narrative

If you see the story differently or want to analyze the numbers on your own terms, it’s quick and straightforward to build your own take: Do it your way.

A good starting point is our analysis highlighting 1 key reward investors are optimistic about regarding Edwards Lifesciences.

Looking for More Opportunities?

Smart investors seize every edge. Unlock untapped ideas and fresh opportunities. You could miss out on standout performers if you only stay with familiar names.

• Capitalize on the rapidly growing world of artificial intelligence by checking out these 25 AI penny stocks to see which companies are driving innovation this year.
• Target high-yield potential in your portfolio. Maximize your returns by browsing these 17 dividend stocks with yields > 3% delivering impressive income streams above 3%.
• Catch undervalued gems that the market may have overlooked and grab your chance with these 917 undervalued stocks based on cash flows based on strong cash flow fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com